ERBB2 and breast carcinoma: The safety, dosimetry, and effectiveness of 99mTc-labeled anti-HER2 nanobodies in diagnostic imaging of HER2 in patients with breast cancer are presently being assessed in a phase I clinical trial (NCT04406686).